Pulmatrix Reports Q1 Results, Confirms Eos SENOLYTIX Merger On Track
PULM is trading near its 52-week low of $1.16 (9.5% above the low).
Summary
Pulmatrix reported Q1 financials with a reduced net loss and confirmed its cash runway extends through the planned merger with Eos SENOLYTIX, a critical strategic transaction.
Key Events · M&A and Partnerships · PULM
-
Q1 2026 Financial Results
Reported a net loss of $1.172 million for the first quarter, an improvement from $1.808 million in Q1 2025. Research and development expenses were less than $0.1 million.
-
Cash Position and Runway
Ended Q1 2026 with $3.3 million in cash and cash equivalents. The company anticipates this cash position is sufficient to fund operations at least through the anticipated Q3 2026 closing of the proposed merger with Eos SENOLYTIX.
-
Eos SENOLYTIX Merger Confirmed
Reaffirmed the definitive merger agreement with Eos SENOLYTIX, expected to close in the third quarter of 2026. This merger will transform Pulmatrix into a gerotherapeutic company.
-
Asset Monetization Strategy
Pulmatrix is actively seeking to out-license or monetize its iSPERSE™ technology and clinical assets, including PUR1900 (advancing to Phase 3 in India), PUR3100 (Phase 2-ready), and PUR1800.
Analysis · PULM · Life Sciences
Pulmatrix provided its first-quarter financial results, showing a reduced net loss and a cash position of $3.3 million. Crucially, the company confirmed its cash runway is sufficient through the anticipated closing of the definitive merger agreement with Eos SENOLYTIX in Q3 2026. This update is important as it provides financial clarity and reaffirms the strategic pivot following the termination of a previous merger, offering a path forward for the micro-cap company.
At the time of this filing, PULM was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.16 to $9.37. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.